You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II
SBC: RaeSedo, LLC Topic: NHLBICurrent treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Critical angle reflection imaging for label-free quantification of molecular interactions
SBC: BIOSENSING INSTRUMENT INC Topic: 400TITLE: Critical angle reflection imaging (CARi) for label-free quantification of molecular interactions SUMMARYMeasuring molecular interactions of proteins are critical for understanding protein functions and cellular processes, for discovery and validating biomarkers, and for developing and screening drugs. In particular, membrane proteins play key roles in many cellular functions and are the lar ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT The development of radiation-induced lung injury (RILI) is a potentially fatal toxicity in cancer patients undergoing thoracic radiotherapy or in individuals exposed to ionizing radiation (IR) from a nuclear incident. The pathobiology of radiation pneumonitis and radiation-induced lung fibrosis (RILF) is complex but includes the deleterious effects of unchecked inflammation (reactive oxyg ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma
SBC: Faknostics, LLC Topic: 102Abstract Melanoma is the deadliest form of skin cancer, affecting an estimated 1.2 million Americans. The disease has a high propensity for dissemination, and metastatic melanoma has a dismal prognosis, with a median survival of only 5–8 months. Healthcare costs for melanoma in 2021 are projected to reach nearly $4 billion, with a rising incidence rate. Despite considerable efforts in recent yea ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
SBC: Medosome Biotec, LLC Topic: NICHDProject Abstract/Summary Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure in which the life expectancy of affected children is severely truncated from unrelenting lactic acidosis and/or from progressive neurological and neuromuscular degeneration. Treatment of PDCD remains a serious, unmet, challenge. Dichloroacetate (DCA) represents the firs ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIMortality rates in intensive care units (ICUs) are unacceptably high and are directly related to the duration of mechanical ventilation that is required to support patients with respiratory failure. For example, acute respiratory distress syndrome (ARDS) is a vexing acute inflammatory lung disease requiring mechanical ventilatory support as the result of severe hypoxemia and respiratory failure. T ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Prevention of White Matter Injury in Premature Infants
SBC: Medosome Biotec, LLC Topic: NICHDABSTRACTUp to 30% of low birth weight preterm infants manifest some form of periventricular white matter injury (PWMI) making it the most common form of brain injury affecting premature infants. PWMI is associated with significant morbidity, as affected individuals may have profound intellectual impairment and cerebral palsy. Highlighting the magnitude of PWMI, each year more than 400,000 infants ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease
SBC: NEURODON, LLC Topic: NIANeurodon LLC proposes to conduct lead optimization and candidate-seeking activities on a novel series of neuroprotective small molecules that shows efficacy in a transgenic model of Alzheimer’s disease (AD). AD is a leading cause of death in the United States, with some estimates ranking it as high as third behind cardiovascular disease and cancer. Despite the enormity of this national public he ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Develop and Commercialize the Bayesian Dose-Response Modeling System and Services
SBC: KS & ASSOCIATES LLC Topic: NIEHSPROJECT SUMMARY Chemical risk assessment is widely applied in industries and regulatory agencies as an important tool to evaluate chemical toxicity in support of chemical registration, safety evaluation, and exposure limitation development. One of the most notable improvements in dose-response assessment - a required quantitative step in risk assessment - is the development of benchmark dose (BMD) ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Application of PPODA-QT for embolization of aneurysms
SBC: ANEUVAS TECHNOLOGIES INC Topic: 101PROJECT SUMMARY/ABSTRACTA cerebral aneurysm is an abnormal enlargement or pouch that forms from a weakened vessel segment in the brain. Often going unnoticed and untreated, an aneurysm can cause a sudden and catastrophic hemorrhage or stroke. Approximately 15 % of patients die from an aneurysm rupture even before receiving medical attention and 25 % of patients die despite medical treatment. Patie ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health